FTC’s Androgel Case May Not Be Best To Tackle Pay-For-Delay

Law360, New York (October 5, 2012, 9:09 PM EDT) -- The Federal Trade Commission has argued that its case over the legality of pay-for-delay settlements involving blockbuster drug Androgel is a strong candidate for high court review, but with two other petitions already pending before the justices in a separate case over the controversial patent deals, attorneys on Friday questioned the agency's position.

The FTC was the third party to seek certiorari over pay-for-delay after a pair of petitions from the defendants in a Third Circuit case over the drug K-Dur 20, which endorsed the FTC's...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.